[Therapeutic failure: importance of genes?].
Drug management can be a difficult task in certain situations because of the variable response observed from one patient to another. Genetic factors affecting the pharmacokinetics and pharmacodynamics of drug reactions could explain the interindividual variability in drug response. Pharmacogenetic analysis provides insight into the molecular mechanisms involved in drug response, with the ultimate goal of achieving optimal drug efficacy and safety. Numerous polymorphisms have been described in genes encoding drug-metabolising enzymes, transporters, and receptors. For some drugs, the impact on drug bioavailability and effect has been elucidated. We review here the molecular basis of interindividual variation in drug response and the methods used to identify individual risk of drug failure or toxicity. Clinical applications, concerning enzymes metabolising drugs (cytochrome P4502D6, thiopurine S-methyltransferase and N-acetyltransferase) provide an illustrative demonstration of the usefulness of pharmacogenetic tests in improving patient management. Clinical validation of these tests and new technologies (real-time PCR, DNA chips) should, in the future promote pharmacogenetics in clinical practice and may be lead to more individualized drug therapy.
Lhermitte
M
M
Laboratoire de Toxicologie, EA 2679, Université de Lille 2, Service Toxicologie et Génopathies, Chru de Lille, Avenue du Pr. J. Leclercq, F 59037 Lille Cedex, France. mlhermitte@chru-lille.fr
Allorge
D
D
Broly
F
F
D000818:Animals; D005823:Genetics; D005838:Genotype; D006801:Humans; D008660:Metabolism / Q000235:genetics / Q000502:physiology; D010597:Pharmacogenetics; D010641:Phenotype; D011110:Polymorphism, Genetic / Q000502:physiology; D017211:Treatment Failure